ArticleFrontiers in immunology2026
Efficacy and safety of upadacitinib in treating immune drift: a single-center, prospective study in China.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: With the widespread use of biologic agents in dermatology, immune drift has emerged as a growing clinical challenge. Although several case reports suggest the therapeutic potential of JAK inhibitors, clinical evidence for upadacitinib-a highly selective JAK1 inhibitor-remains limited. Methods: A prospective study evaluated the efficacy and safety of upadacitinib in patients with immune drift at the Department of Dermatology, First Affiliated Hospital of Guangxi Medical University, from December 2024 to September 2025. Results: Eleven patients exhibiting immunological drift (including eight with PSO-AD and three with AD-PSO) were recruited for this investigation, with a mean age of 37.4 ± 18.8 years. Following four weeks of treatment, their IGA 0/1 response rates reached 62.5%. Their EASI scores decreased markedly from 18.0 (12.4-24.4) to 2.5 (0.52-13.1) ( Conclusion: Our findings suggest that upadacitinib is effective and safe in managing immune drift, with rapid improvements in disease control and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.